The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells.
Previous findings indicated that the activated leukocyte cell adhesion molecule (ALCAM) is expressed by tumors and plays a role in tumor biology. In this study, we show that ALCAM is shed from epithelial ovarian cancer (EOC) cells in vitro, leading to the generation of a soluble ALCAM (sALCAM), consisting of most of the extracellular domain. A similar sALCAM molecule was also found in the ascitic fluids and sera from EOC patients, suggesting that this process also occurs in vivo. sALCAM is constitutively produced by EOC cells, and this process can be enhanced by cell treatment with pervanadate, phorbol 12-myristate 13-acetate (PMA), or epidermal growth factor (EGF), a known growth factor for EOC. Pharmacologic inhibitors of matrix metalloproteinases (MMP) and of a disintegrin and metalloproteases (ADAM), and the tissue inhibitor of metalloproteinase-3, significantly inhibited sALCAM release by EOC cells. The ADAM17/TACE molecule was expressed in EOC cell lines and ADAM17/TACE silencing by specific small interfering RNA-reduced ALCAM shedding. In addition, inhibitors of ADAM function blocked EOC cell motility in a wound-healing assay. Conversely, a recombinant antibody blocking ALCAM adhesive functions and inducing ALCAM internalization enhanced EOC cell motility. Altogether, our data suggest that the disruption of ALCAM-mediated adhesion is a relevant step in EOC motility, and ADAM17/TACE takes part in this process, which may be relevant to EOC invasive potential.
Rosso
Ombretta
O
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Piazza
Tiziana
T
Bongarzone
Italia
I
Rossello
Armando
A
Mezzanzanica
Delia
D
Canevari
Silvana
S
Orengo
Anna Maria
AM
Puppo
Andrea
A
Ferrini
Silvano
S
Fabbi
Marina
M
D051722:ADAM Proteins / Q000235:genetics / Q000378:metabolism*; D000072198:ADAM17 Protein; D015703:Antigens, CD / Q000097:blood*; D001202:Ascitic Fluid / Q000378:metabolism; D002273:Carcinogens / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D015816:Cell Adhesion Molecules, Neuronal / Q000097:blood*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology*; D017077:Culture Media, Conditioned / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D005326:Fetal Proteins; D006801:Humans; D009361:Neoplasm Invasiveness; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology*; D034741:RNA, Small Interfering; D012995:Solubility; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives / Q000494:pharmacology; D014638:Vanadates / Q000494:pharmacology; D020410:Activated-Leukocyte Cell Adhesion Molecule
D051722:ADAM Proteins; D000072198:ADAM17 Protein; D015703:Antigens, CD; D002273:Carcinogens; D015816:Cell Adhesion Molecules, Neuronal; D017077:Culture Media, Conditioned; D004791:Enzyme Inhibitors; D005326:Fetal Proteins; D034741:RNA, Small Interfering; D013755:Tetradecanoylphorbol Acetate; D014638:Vanadates; C105613:ALCAM protein, human; D020410:Activated-Leukocyte Cell Adhesion Molecule; C076715:pervanadate; C016658:phorbolol myristate acetate; C000606462:ADAM17 protein, human